Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
11/2003
11/11/2003US6645527 Stabilized sustained release tramadol formulations
11/11/2003US6645494 An antibody, or a binding fragment thereof, specific for human CD40L antigen conjugated to a Type I ribosome inactivating protein
11/11/2003US6645484 Endothelial cell transmembrane tyrosine kinase ligand
11/11/2003US6645482 Sulfated proteoglycan; one or more of a hexosamine sulfate,a flavone, olive kernel extract, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of CRH, caffeine, and a polyamine.
11/11/2003CA2272098C Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
11/11/2003CA2185932C Use of a least one peptide in a cosmetic composition or for the preparation of a drug
11/11/2003CA2104636C Use of kallikrein inhibitor for the production of a pharmaceutical for the prophylaxis and therapy of certain diseases
11/06/2003WO2003091456A1 A dna enzyme to inhibit plasminogen activator inhibitor-1
11/06/2003WO2003091432A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
11/06/2003WO2003091414A2 Adipocyte complement related protein zacrp8
11/06/2003WO2003091271A1 Alternatively spliced nucleic acid molecules
11/06/2003WO2003091259A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
11/06/2003WO2003091258A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003WO2003091256A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
11/06/2003WO2003091252A1 Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases
11/06/2003WO2003091247A2 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
11/06/2003WO2003091242A1 Novel thiol derivative, process for producing the same and use thereof
11/06/2003WO2003091239A1 Estrogen receptor modulators
11/06/2003WO2003091232A2 Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
11/06/2003WO2003091229A1 Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
11/06/2003WO2003091227A1 Tachykinin receptor antagonists
11/06/2003WO2003091225A1 Substituted pyrazine derivatives
11/06/2003WO2003091223A1 Pyrimidine derivative
11/06/2003WO2003091221A1 Celecoxib forms
11/06/2003WO2003091215A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo’ b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
11/06/2003WO2003091214A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo
11/06/2003WO2003091189A1 Cannabinoids
11/06/2003WO2003090912A1 Pyrrolo-triazine aniline compounds useful as kinase inhibitors
11/06/2003WO2003090870A1 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
11/06/2003WO2003090818A2 Drug-delivery endovascular stent and method for treating restenosis
11/06/2003WO2003090769A1 Preparation containing a mixture of picrorrhiza and ginkgo for the relief of disease
11/06/2003WO2003090758A1 Method for treating inflammatory disorders
11/06/2003WO2003090752A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003WO2003090751A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003WO2003090748A1 Use of compounds having ccr antagonism
11/06/2003WO2003090737A2 Methods and compositions for treatment of cancer pain
11/06/2003WO2003090731A1 Use of gabab receptor positive modulators in gastro-instestinal disorders
11/06/2003WO2003090730A1 Novel crystalline forms of celecoxib and other compounds
11/06/2003WO2003090726A2 Chewable soft capsule
11/06/2003WO2003090684A2 Polymer compositions containing a macrocyclic triene compound
11/06/2003WO2003090682A2 Treatment and prevention of pulmonary conditions
11/06/2003WO2003090662A2 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
11/06/2003WO2003090514A2 Adipocyte complement related protein zacrp14
11/06/2003WO2003080125A3 Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
11/06/2003WO2003076458A3 Selective dipeptide inhibitors of kallikrein
11/06/2003WO2003075685A3 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
11/06/2003WO2003057166A3 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003WO2003035626A3 Azole derivatives and pharmaceutical compositions containing them
11/06/2003WO2003035005A3 Heteroindanes: a new class of potent cannabimimetic ligands
11/06/2003WO2003032985A3 Concomitant oral and topical administration of anti - infective agents
11/06/2003WO2003031939A3 Protein modification and maintenance molecules
11/06/2003WO2003027263A3 Proteins associated with cell growth, differentiation, and death
11/06/2003WO2003018640A3 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
11/06/2003WO2003013428A3 Nutritional supplements and methods of using same
11/06/2003WO2003007686A3 Use of copper chelators to inhibit the inactivation of protein c
11/06/2003WO2002092773A3 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
11/06/2003WO2002083854A9 Antibodies to vla-1
11/06/2003WO2002083083A3 Pharmaceutically active compounds and methods of use
11/06/2003WO2002076979A8 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
11/06/2003WO2002072631A3 Mhc molecule constructs and their usesfor diagnosis and therapy
11/06/2003WO2002070657A8 93870, a human g-protein coupled receptor and uses therefor
11/06/2003WO2002070509A8 Antagonists of mcp-1 function and methods of use thereof
11/06/2003WO2002060949A8 Glycoforms a fas ligand inhibitory protein analog
11/06/2003WO2002060900A8 Antagonists of mcp-1 function and methods of use thereof
11/06/2003WO2002051983A3 Novel compounds and compositions as cathepsin inhibitors
11/06/2003WO2002034204A3 Calcilytic compounds
11/06/2003WO2002032435A3 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade
11/06/2003WO2002024891A9 B7-like molecules and uses thereof
11/06/2003WO2002002096A8 Oral compositions comprising host-response modulating agent
11/06/2003US20030208249 Energy-activated targeted cancer therapy
11/06/2003US20030208084 Sulfonamides and derivatives thereof that modulate the activity of endothelin
11/06/2003US20030208079 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for proph7ylaxis of cardiovascular disorders
11/06/2003US20030208067 Inhibitors of protein kinase for the treatment of disease
11/06/2003US20030208058 B7-like polypeptides and polynucleotides
11/06/2003US20030208046 Pseudo native chemical ligation
11/06/2003US20030208045 Binds to Osteoclastogenesis Inhibitory Factor (OCIF) binding molecule (OBM)
11/06/2003US20030207931 Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1h-1,2,4-triazole for the treatment of autoimmune diseases
11/06/2003US20030207923 Treatment of autoimmune disease, inflammation and allergy; inhibits release of tumour necrosis factor
11/06/2003US20030207919 For treating, preventing, reducing inflammation, pain, fever,gastrointestinal disorders; decreasing gastrointestinal, renal and other toxicities resulting from use of nonsteroidal antiinflammatory drugs; multiplicity of compounds
11/06/2003US20030207906 Chemical compounds
11/06/2003US20030207905 Method of treating pain using nalbuphine and opioid antagonists
11/06/2003US20030207897 Selective inhibitors of cyclooxygenase-2
11/06/2003US20030207896 Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts
11/06/2003US20030207895 Tissue factor antagonists and methods of use thereof
11/06/2003US20030207893 Antihistamines such as (5-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone, used as antiinflammatory, antiarthritic or bronchodilator agents and/or immunology modulators
11/06/2003US20030207892 Heterocyclic amines such as N-(Pyridin-4-yl)-(1-(4-fluoro-benzyl)indol-3-yl)glyoxylamide, used for prophylaxis of skin disorders, rheumatic diseases or arthritis
11/06/2003US20030207881 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
11/06/2003US20030207879 Preferential G protein coupled receptor antagonists, such as 8-(3-amino-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-3,7-dihydro -1H-purine-2,6-dione, used for prophylaxis of asthma, autoimmune diseases or retinopathy
11/06/2003US20030207878 Drugs used as angiogenesis inhibitors, vascular permeability or endothelial growth factor antagonists, for prophylaxis of cancer, diabetes, psoriasis, arthritis, autoimmune diseases, inflammation or scar formation
11/06/2003US20030207870 Aryl ureas with angiogenisis inhibiting activity
11/06/2003US20030207867 Method of treating a male or female animal in the treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit comprising treating said animal with an effective amount of a pharmaceutical composition with carriers
11/06/2003US20030207858 Selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function.
11/06/2003US20030207850 Hormone replacement therapy
11/06/2003US20030207846 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003US20030207834 The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.
11/06/2003US20030207796 Specifically bind a carbohydrate target wherein sialic acid is linked at the nonreducing terminus of a glycoside to a galactose or galactosamine residue through an alpha 2-6 linkage are able to inhibit the conversion of human Factor X
11/06/2003US20030207450 Derived from the neuroretina of the eye ex vivo and in vivo
11/06/2003US20030207434 Phosphodiesterases
11/06/2003US20030207403 For diagnosis or treatment of diseases with beta 10 polypeptides and alpha 2/ beta 10 heterodimers or their respective binding agents, such as thyroid gland disorders
11/06/2003US20030207318 Kinesin-like motor protein
1 ... 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 ... 1272